What does this research mean for the field?

A regimen of low-dose 10-day decitabine combined with venetoclax induces rapid measurable residual disease (MRD) negativity, good tolerability, and high long-term survival in acute myeloid leukemia patients ineligible for intensive therapy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy and safety of a low-dose 10-day decitabine regimen combined with venetoclax in patients with acute myeloid leukemia.

August 22, 2026Annals of HematologyOpen Access

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in De Novo AML

View Full Paper

Ask AI

Bookmark

Authors

JWJunqing WuCell Technology (China)XLXueping LuoZhejiang Chinese Medical University XLXiaoyu LiuZhejiang Chinese Medical University

Discussion

Member takes

Implication

Retrospective study demonstrates high remission rates and rapid MRD negativity with low-dose decitabine and venetoclax in AML, indicating an effective option for unfit patients.

Key Points

To evaluate the efficacy and safety of a low-dose 10-day decitabine regimen combined with venetoclax in patients with acute myeloid leukemia.
Retrospective analysis of 37 patients with acute myeloid leukemia treated with decitabine (6 mg/m² for 10 days) and venetoclax (for 14 days).
Patients were assessed for response rates, minimal residual disease (MRD) status, survival outcomes over a median follow-up of 40.0 months, and adverse events.
The composite complete remission (CRc) rate was 78.4% overall (88.9% in favorable and 75.0% in intermediate/adverse ELN-2022 risk groups), with 79.3% of responders achieving MRD negativity after the first cycle.
Median overall survival was 36.1 months, with 36-month overall survival and event-free survival rates of 35.0% and 40.4%, respectively.
Multivariate analysis showed that an ECOG performance status < 3 and non-complex karyotype were associated with significantly superior overall survival, while hematologic toxicities were the most frequent adverse events.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/6a895f2aca7ade938187d91a https://doi.org/10.1007/s00277-026-07222-7

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study demonstrates high remission rates and rapid MRD negativity with low-dose decitabine and venetoclax in AML, indicating an effective option for unfit patients.

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in De Novo AML

Discussion

Member takes

Implication

Key Points

Cite This Study

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in De Novo AML

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider